Viridian Therapeutics (VRDN) 10-K2018 FY Annual report

Filed: 14 Mar 19, 10:45am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ABC, Abigail, antiapoptotic, antifibrotic, Ari, ATLL, biometric, BLA, Blueprint, BMS, chemoimmunotherapy, Circle, CLL, contributor, convey, CT, dehydrogenase, DLBCL, explained, GDPR, germinal, Helsinn, incentivize, lactate, LDH, lethal, leukemic, LLS, Lyda, Malachite, mixed, node, NOL, nonbinding, NY, opportunistic, parallel, pocket, predisposed, predominant, prosurvival, pumping, Rainier, remission, remlarsen, shareholder, spot, startup, subgroup, sutured, thyroid, tract, typified, ulceration, unconstitutional, undergone, uninvested, unrealized, version, veteran, vorinostat, withdrew, worse, Zolinza, Zweiman

Removed: advisor, analyze, analyzed, assay, assigned, assumption, attributed, avoid, bill, biopsy, CEO, CFO, classification, COBRA, collected, constituting, contact, diminution, documented, embezzlement, employer, entitle, estate, exclusively, explore, floor, inattention, interpret, investigated, larceny, lawful, line, neglect, noncash, omission, partnership, personalized, plasma, practical, procedure, Quest, reaction, refrain, regimen, regulating, resign, Riccitelli, Samuel, Seymour, shelf, solid, Tamara, theft, unreimbursed, urine, vacation, visit

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated VRDN transcripts

VRDN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Miragen Therapeutics, Inc.:

We consent to the incorporation by reference in the registration statements (No. 333‑217084) on Form S-3 and (Nos. 333‑216112 and 333-223672) on Form S-8 of Miragen Therapeutics, Inc. of our report dated March 14, 2019 with respect to the consolidated balance sheets of Miragen Therapeutics, Inc. as of December 31, 2018 and 2017, and the related consolidated statements of operations and comprehensive loss, changes in preferred stock and stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements) which report appears in the December 31, 2018 annual report on Form 10‑K of Miragen Therapeutics, Inc.

/s/ KPMG LLP

Denver, Colorado

March 14, 2019